文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌质子放疗相关食管炎的LKB NTCP建模

Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy.
PubMed 文献 · Radiother Oncol · 2020-04-30

本研究回顾性分析328例接受被动散射质子治疗的NSCLC患者,基于LKB模型建立预测6个月内≥2级放射性食管炎的NTCP模型。最优参数为n=0.24、m=0.51、TD50=44.83 Gy(RBE),乐观校正AUC为0.783,Hosmer-Lemeshow检验显示预测与观察显著一致,Bootstrap验证模型稳健,但体积效应小于光子放疗人群。

要点

  • 质子放疗后≥2级食管炎发生率为41.5%,未观察到4-5级事件。
  • LKB最优参数:n=0.24、m=0.51、TD50=44.83 Gy(RBE)。
  • 模型区分度良好(AUC=0.783),校准与内部验证均满意。

核心结论

  • LKB NTCP模型可较好预测NSCLC质子放疗后≥2级放射性食管炎,且对相似未来人群稳健。

研究设计与样本

  • 回顾性研究,纳入本机构328例接受被动散射质子治疗的NSCLC患者。
  • 食管炎按CTCAE v3.0分级,主要终点为首次治疗后6个月内≥2级放射性食管炎。
  • 采用最大似然估计确定LKB模型参数,并以Bootstrap进行内部验证。

主要发现

  • 136例(41.5%)发生2-3级放射性食管炎,无4-5级事件报告。
  • 最优LKB参数为n=0.24、m=0.51、TD50=44.83 Gy(相对生物效应)。
  • 乐观校正AUC为0.783,Hosmer-Lemeshow检验显示预测与观察显著一致。
  • Bootstrap验证表明模型对相似未来人群稳健。

关键数值与推荐

  • LKB模型参数:n=0.24、m=0.51、TD50=44.83 Gy(RBE)。
  • 模型区分度:乐观校正AUC=0.783。
  • 体积效应小于既往光子放疗人群观察值。

临床怎么用

  • 该模型可用于质子放疗前预测NSCLC患者≥2级放射性食管炎风险,辅助计划优化。
  • 因体积效应较小,质子放疗计划中食管剂量体积约束需考虑与光子放疗的差异。

局限性

  • 本研究为单中心回顾性分析,需外部验证。
  • 仅纳入被动散射质子治疗患者,结论不可直接外推至其他质子技术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop and test an Lyman-Kutcher-Burman (LKB) normal tissue complication probability (NTCP) model to predict radiation-induced esophagitis (RE) in non-small cell lung cancer (NSCLC) patients receiving passive-scattering proton therapy (PSPT). MATERIAL AND METHODS: We retrospectively reviewed 328 NSCLC patients receiving PSPT at our institution. Esophagitis severity was graded by physicians according to the Common Toxicity Criteria for Adverse Events version 3.0, and the primary endpoint was grade ≥2 RE within 6 months from the first treatment. LKB model parameters (n, m, and TD50) were determined using maximum likelihood estimation. Overall performance of the model was quantified by Nagelkerke's R2 and the scaled Brier score. Discriminative ability was evaluated using the area under the receiver operating curve (AUC), and calibration was assessed with the Hosmer-Lemeshow goodness-of-fit test. Bootstrap internal validation was performed to assess the model uncertainty and generalizability. RESULTS: Grade 2-3 RE was observed in 136 (41.5%) patients, and no grade 4-5 RE was reported. The optimal LKB parameters were: n = 0.24, m = 0.51, and TD50 = 44.83 Gy (relative biological effectiveness). The optimism-corrected AUC was 0.783, and the Hosmer-Lemeshow test showed significant agreement between predicted and observed morbidity. Bootstrap validation verified that the model was robust to similar future populations. CONCLUSION: Our LKB NTCP model to predict grade ≥2 RE in NSCLC patients who received PSPT showed good predictive performance and robustness to similar future populations, and a smaller volume effect than the previously observed in photon-treated populations. External validation of the model is warranted.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Chen M, Sun J, et al. Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiother Oncol. 2020. PMID: 32220701. doi:10.1016/j.radonc.2020.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。